Compare BIO-TECHNE Corp (TECH) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs ProShares UltraPro QQQ ETF — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while ProShares UltraPro QQQ ETF trades at $71.53. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while ProShares UltraPro QQQ ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| TECH | TQQQ | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $72.48 | $87.22 |
52-Week Low | $43.31 | $37.89 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $72.16, down 0.29% on the day. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. Recent news highlights its amplified returns during the AI boom but warns of structural costs like volatility decay. The ETF's performance is closely tied to large-cap tech earnings and market sentiment.
The outlook for TQQQ hinges on continued tech sector strength, particularly AI-driven growth, but risks include high volatility and decay from daily rebalancing. Investors face amplified gains or losses, making it suitable only for those comfortable with significant risk. Monitoring underlying index performance and tech earnings is critical for timing entries and exits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
